Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Jolly

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Regulatory Toxicology and Pharmacology : RTP|February 7, 2015
An evaluation of in-house and off-the-shelf in silico models: implications on guidance for mutagenicity assessmentRobert Jolly, Kausar Begam Riaz Ahmed, Craig Zwickl, et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis|June 9, 2026
An evaluation of common pharmaceutical solvents in the in vitro micronucleus assayJessica Noteboom, Robert Smith, Abigail Feiner, et al.
Regulatory Toxicology and Pharmacology : RTP|September 26, 2024
N-Nitrosamine drug substance related impurities (NDSRIs) - A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 DaJoel Bercu, Olivier Dirat, Krista Dobo, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2002
The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone classRichard J Sciotti, Marina Pliushchev, Paul E Wiedeman, et al.
Regulatory Toxicology and Pharmacology : RTP|September 7, 2024
Safety assessment of protein A and derivation of a parenteral health-based exposure limitJessica C Graham, Sathanandam S Anand, Joel Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|February 11, 2012
In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: an industry surveyKrista L Dobo, Nigel Greene, Charlotta Fred, et al.
Regulatory Toxicology and Pharmacology : RTP|January 20, 2016
It's difficult, but important, to make negative predictionsRichard V Williams, Alexander Amberg, Alessandro Brigo, et al.
Biotechnology and Bioengineering|January 10, 2026
Assessment and Control of Host Cell Proteins in Biologics: Survey of Industry Practices and a Vision for HarmonizationJessica Graham, Sathanandam S Anand, Joel Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|May 31, 2023
Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs)Joel P Bercu, Melisa Masuda-Herrera, Alejandra Trejo-Martin, et al.
Regulatory Toxicology and Pharmacology : RTP|February 1, 2026
Ames Concordance with the In Vivo Transgenic Rodent (TGR) Gene Mutation Assay for NDSRIs and Relative In Vivo TGR Potency with Nitrosamines with Robust Dose-Response Carcinogenicity DataRobert Jolly, Alejandra Trejo-Martin, Joel P Bercu, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Regulatory Toxicology and Pharmacology : RTP|February 7, 2015
An evaluation of in-house and off-the-shelf in silico models: implications on guidance for mutagenicity assessmentRobert Jolly, Kausar Begam Riaz Ahmed, Craig Zwickl, et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis|June 9, 2026
An evaluation of common pharmaceutical solvents in the in vitro micronucleus assayJessica Noteboom, Robert Smith, Abigail Feiner, et al.
Regulatory Toxicology and Pharmacology : RTP|September 26, 2024
N-Nitrosamine drug substance related impurities (NDSRIs) - A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 DaJoel Bercu, Olivier Dirat, Krista Dobo, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2002
The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone classRichard J Sciotti, Marina Pliushchev, Paul E Wiedeman, et al.
Regulatory Toxicology and Pharmacology : RTP|September 7, 2024
Safety assessment of protein A and derivation of a parenteral health-based exposure limitJessica C Graham, Sathanandam S Anand, Joel Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|February 11, 2012
In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: an industry surveyKrista L Dobo, Nigel Greene, Charlotta Fred, et al.
Regulatory Toxicology and Pharmacology : RTP|January 20, 2016
It's difficult, but important, to make negative predictionsRichard V Williams, Alexander Amberg, Alessandro Brigo, et al.
Biotechnology and Bioengineering|January 10, 2026
Assessment and Control of Host Cell Proteins in Biologics: Survey of Industry Practices and a Vision for HarmonizationJessica Graham, Sathanandam S Anand, Joel Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|May 31, 2023
Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs)Joel P Bercu, Melisa Masuda-Herrera, Alejandra Trejo-Martin, et al.
Regulatory Toxicology and Pharmacology : RTP|February 1, 2026
Ames Concordance with the In Vivo Transgenic Rodent (TGR) Gene Mutation Assay for NDSRIs and Relative In Vivo TGR Potency with Nitrosamines with Robust Dose-Response Carcinogenicity DataRobert Jolly, Alejandra Trejo-Martin, Joel P Bercu, et al.
Pageof 2